CBR4: Enzyme for The TCA Cycle and Potential Drug Targets (G84869)

Target Name: CBR4

NCBI ID: G84869

CBR4

CBR4: Enzyme for The TCA Cycle and Potential Drug Targets

CBR4 (Quinone Reductase CBR4) is a gene that encodes a protein known as CBR4. CBR4 is a key enzyme in the quinone reduction pathway, a critical metabolic pathway that is involved in the production of many essential molecules in the body. This pathway is also known as the tricarboxylic acid (TCA) cycle or citric acid cycle.

The quinone reduction pathway is a critical pathway for the production of many essential molecules, including aromatic amino acids, which are important for the structure and function of many proteins. This pathway is also involved in the production of other molecules, including energy-carrying molecules such as ATP and NADH.

CBR4 is the enzyme that catalyzes the quinone reduction step of the TCA cycle. This step is critical for the production of aromatic amino acids, as it involves the reduction of the quinone molecule to the amino acid tryptophan. Tryptophan is the most abundant aromatic amino acid and is involved in the production of many important molecules, including proteins, nucleic acids, and neurotransmitters.

CBR4 is a protein that is expressed in many different tissues and cells in the body. It is highly expressed in the liver, where it is involved in the production of aromatic amino acids. It is also expressed in the heart, where it is involved in the production of atrial natriuretic peptide (ANP), a molecule that helps to regulate blood pressure.

CBR4 is a potential drug target for several diseases. One of the main targets for CBR4 is the treatment of hypertension, which is a common condition that can lead to a range of serious health problems, including heart disease, stroke, and kidney damage. Hypertension is a condition in which the blood pressure is consistently high, and it is estimated that it affects more than 90 million people in the United States alone.

Another potential target for CBR4 is the treatment of diabetes. Diabetes is a condition in which the body is unable to produce or effectively use insulin, leading to high levels of blood sugar. CBR4 has been shown to be involved in the production of insulin, and Therefore it is a potential target for the treatment of diabetes.

In addition to its potential as a drug target, CBR4 is also a potential biomarker for several diseases. For example, high levels of CBR4 have been shown to be associated with the development of certain types of cancer, including breast and colorectal cancer. Additionally, CBR4 has been shown to be involved in the production of many diseases, including heart disease, diabetes, and neurodegenerative diseases.

CBR4 is also a potential target for the treatment of other conditions, including respiratory diseases, liver diseases, and renal diseases. For example, CBR4 has been shown to be involved in the production of the protein known as bradykinin, which is involved in the regulation of blood pressure. Additionally, CBR4 has been shown to be involved in the production of the molecule known as heat shock protein (HSP), which is involved in the regulation of stress responses.

In conclusion, CBR4 is a gene that encodes a protein that is involved in the quinone reduction pathway of the TCA cycle. CBR4 is a key enzyme in this pathway and is involved in the production of many essential molecules, including aromatic amino acids. As a result, CBR4 is a potential drug target for the treatment of hypertension, diabetes, and other diseases. Additionally, CBR4 is also a potential biomarker for these diseases, as well as for many others.

Protein Name: Carbonyl Reductase 4

Functions: Component of the heterotetramer complex KAR (3-ketoacyl-[acyl carrier protein] reductase or 3-ketoacyl-[ACP] reductase) that forms part of the mitochondrial fatty acid synthase (mtFAS). Beta-subunit of the KAR heterotetramer complex, responsible for the 3-ketoacyl-ACP reductase activity of the mtFAS, reduces 3-oxoacyl-[ACP] to (3R)-hydroxyacyl-[ACP] in a NADPH-dependent manner with no chain length preference, thereby participating in mitochondrial fatty acid biosynthesis (PubMed:25203508). The homotetramer has NADPH-dependent quinone reductase activity (in vitro), hence could play a role in protection against cytotoxicity of exogenous quinones (PubMed:19000905). As a heterotetramer, it can also reduce 9,10-phenanthrenequinone, 1,4-benzoquinone and various other o-quinones and p-quinones (in vitro) (PubMed:19000905, PubMed:19571038, PubMed:25203508)

The "CBR4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CBR4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets